Colorectal News and Research

RSS

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011

DiagnoCure reports net loss of $1,601,439 for second quarter 2011

DiagnoCure, Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, today reported financial and operation results for the second quarter of fiscal 2011.

7 Jun 2011

Cancer risk assessment in Lynch syndrome

Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associated with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

Women with ovarian cancer do not benefit from CA-125 and transvaginal ultrasound

In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase in invasive medical procedures and associated harms as a result of being screened, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

Recommendations on new cancer drug review process fall short in several ways: CCAC

While the Colorectal Cancer Association of Canada congratulates Quebec Health Minister Yves Bolduc on the recommendations of the report of the Working Group on the evaluation process of new anti cancer medications (Rapport du Groupe de travail sur le processus d'évaluation des médicaments anticancéreux) recently issued, the CCAC notes that the recommendations fall short in several important ways.

4 Jun 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

Five years after cancer treatment, many survivors still suffer symptoms

When people finish treatment for cancer, they want to bounce back to their former vital selves as quickly as possible. But a new Northwestern Medicine study -- one of the largest survivor studies ever conducted - shows many survivors still suffer moderate to severe problems with pain, fatigue, sleep, memory and concentration three to five years after treatment has ended.

4 Jun 2011

Elevated CRP levels predict poor prognosis of breast cancer

Levels of C-reactive protein (CRP) are increased in response to acute inflammation, infection and tissue damage. There are also reports that CRP levels are elevated because of cancer.

3 Jun 2011

Innovative bowel screening kits effective in detecting pre-cancerous growths

New bowel screening kits, expected soon for England and Scotland, are more sensitive at picking up pre-cancerous growths in the left-side of the bowel than the right-side because the growths are shaped differently.

1 Jun 2011

FDA approves Oceana's Solesta for treatment of fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.

31 May 2011

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.

27 May 2011

Folic acid during pregnancy reduces rate of colon cancer in offspring

Folic acid supplements given to pregnant and breast-feeding rats reduced the rate of colon cancer in their offspring by 64 per cent, a new study has found.

27 May 2011

Conference reviews recent evidence that links aspirin use with reduced risk of several cancers

Recent evidence linking aspirin use with a reduced risk of several cancers could change the risk benefits analysis in favour of wider use of aspirin, concluded a meeting organized by the Aspirin Foundation.

25 May 2011

Olympus ScopeGuide for colonoscopy receives U.S. approval

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products among other core businesses, announces that its revolutionary ScopeGuide- technology can now be used within the United States.

From Evident Corporation - Life Sciences 25 May 2011

New cancer study finds benefit in old therapy

Cancer patients who used a 5,000-year-old combination of gentle exercise and meditation experienced significantly higher wellbeing levels, improved cognitive functioning and less inflammation compared to a control group, new University of Sydney research has found.

24 May 2011

Fibre rich diet and healthy lifestyle prevents bowel cancer

According to leading researchers there is more evidence than ever before that fiber-rich foods prevent bowel cancer. They analyzed the most up-to-date research on the disease and said there is now “convincing” evidence that foods containing fiber can offer protection. An earlier 2007 concluded that dietary fiber “probably” cuts the risk of the disease but this new analysis is stronger they say. New evidence includes research that says three servings a day of cereal fiber and whole grains reduce the risk.

24 May 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

Coordinated efforts required to close gaps in preventive behavior: American Cancer Society

A new report from the American Cancer Society details cancer control efforts and outlines improvements as well as gaps in preventive behavior that contribute to cancer mortality.

21 May 2011

The Chartis Group and HPMG partner to help providers improve outpatient care delivery systems

HealthPartners Medical Group and Clinics and The Chartis Group today announce a unique collaboration to help hospitals and health systems achieve superior performance in health care quality and patient service, while simultaneously lowering costs.

20 May 2011

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.

19 May 2011

Colorectal News and Research

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

DiagnoCure reports net loss of $1,601,439 for second quarter 2011

Cancer risk assessment in Lynch syndrome

Women with ovarian cancer do not benefit from CA-125 and transvaginal ultrasound

Recommendations on new cancer drug review process fall short in several ways: CCAC

Researcher to evaluate new approach for treatment of triple-negative breast cancer

Five years after cancer treatment, many survivors still suffer symptoms

Elevated CRP levels predict poor prognosis of breast cancer

Innovative bowel screening kits effective in detecting pre-cancerous growths

FDA approves Oceana's Solesta for treatment of fecal incontinence

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Folic acid during pregnancy reduces rate of colon cancer in offspring

Conference reviews recent evidence that links aspirin use with reduced risk of several cancers

Olympus ScopeGuide for colonoscopy receives U.S. approval

New cancer study finds benefit in old therapy

Fibre rich diet and healthy lifestyle prevents bowel cancer

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Coordinated efforts required to close gaps in preventive behavior: American Cancer Society

The Chartis Group and HPMG partner to help providers improve outpatient care delivery systems

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News